Immunological effects of behavioral activation with exercise in major depression: an exploratory randomized controlled trial

F Euteneuer, K Dannehl, A Del Rey, H Engler, M Schedlowski, W Rief, F Euteneuer, K Dannehl, A Del Rey, H Engler, M Schedlowski, W Rief

Abstract

Major depression (MD) is associated with peripheral inflammation and increased cardiovascular risk. Regular physical exercise can have anti-inflammatory effects. The present study examined whether behavioral activation with exercise affects inflammatory processes in MD. Ninety-eight patients with MD were randomly assigned to cognitive-behavioral therapy (CBT) emphasizing exercise during behavioral activation (CBT-E), CBT with pleasurable low-energy activities as an active control condition (CBT-C) or a passive waiting list control group (WL). Plasma levels of C-reactive protein (CRP), interleukin (IL)-6, IL-10, lipopolysaccharide (LPS)-stimulated IL-6 production, and blood immune cell counts were analyzed at baseline and weeks 8 (post-behavioral activation) and 16 (post-treatment). Thirty non-depressed age- and sex-matched controls were included to examine potential immunological alterations in MD at baseline. Patients with MD exhibited higher levels of CRP, higher neutrophil and monocyte counts, lower IL-10 levels and reduced LPS-stimulated IL-6 production compared to controls (P<0.001-0.045). Multilevel modeling indicated that CBT-E was associated with increased anti-inflammatory IL-10 at weeks 8 and 16 compared to CBT-C and WL (P=0.004-0.018). CBT-E did not significantly affect other immunological makers in the total sample. A subgroup analysis including patients with potentially higher cardiovascular risk (CRP ⩾1 μg ml-1) indicated that CRP was reduced in CBT-E compared to CBT-C (P<0.007) and marginally reduced compared to WL (P<0.085) after week 16. The present findings provide new insights into immunological effects of behavioral treatments against depression. Behavioral activation in conjunction with exercise may have the potential to reverse, in part, immunological alterations in MD.

Conflict of interest statement

WR received honoraria for presentations and consultation about placebo mechanisms from Berlin Chemie, Bayer and Heel. ClinicalTrials.gov Identifier: NCT01464463 (The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients with Major Depression). The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow of participants through each stage of the trial. CBT-C, cognitive-behavioral therapy control condition; CBT-E, cognitive-behavioral therapy with physical activity; CRP, C-reactive protein; ITT, intention-to-treat; WL, waitlist control group.
Figure 2
Figure 2
Circulating levels of anti-inflammatory interleukin-10 (IL-10) from baseline to week 8 (post-behavioral activation), and to week 16 (post-treatment) by treatment group. Values are estimated marginal means (s.e.m.) from multilevel modeling. Pairwise contrasts for cognitive-behavioral therapy with exercise (CBT-E) versus cognitive-behavioral therapy with pleasurable low-energy activities (CBT-C, active control condition) versus waitlist (WL, passive control condition): *P<0.05.
Figure 3
Figure 3
Subgroup analysis (N=42) of patients with potentially elevated cardiovascular risk (CRP ⩾1 μg ml−1). Circulating levels of C-reactive protein (CRP) from baseline to week 8 (post-behavioral activation), and to week 16 (post-treatment) by treatment group. Values are estimated marginal means (s.e.m.) from multilevel modeling. Pairwise contrasts for cognitive-behavioral therapy with exercise (CBT-E) versus cognitive-behavioral therapy with pleasurable low-energy activities (CBT-C, active control condition) versus waitlist (WL, passive control condition): *P<0.05, #P<0.1.

References

    1. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.
    1. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171–186.
    1. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009; 23: 936–944.
    1. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2015; 16: 22–34.
    1. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry 2015; 172: 1075–1091.
    1. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46–56.
    1. Dhabhar FS, Burke HM, Epel ES, Mellon SH, Rosser R, Reus VI et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res 2009; 43: 962–969.
    1. Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009; 42: 182–188.
    1. Voorhees JL, Tarr AJ, Wohleb ES, Godbout JP, Mo X, Sheridan JF et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS ONE 2013; 8: e58488.
    1. Roque S, Correia-Neves M, Mesquita AR, Palha JA, Sousa N. Interleukin-10: a key cytokine in depression? Cardiovasc Psychiatry Neurol 2009; 2009: 187894.
    1. Pan Y, Lin W, Wang W, Qi X, Wang D, Tang M. The effects of central pro-and anti-inflammatory immune challenges on depressive-like behavior induced by chronic forced swim stress in rats. Behav Brain Res 2013; 247: 232–240.
    1. Mesquita AR, Correia-Neves M, Roque S, Castro AG, Vieira P, Pedrosa J et al. IL-10 modulates depressive-like behavior. J Psychiatr Res 2008; 43: 89–97.
    1. Holtzman S, Abbey SE, Chan C, Bargman JM, Stewart DE. A genetic predisposition to produce low levels of IL-10 is related to depressive symptoms: a pilot study of patients with end stage renal disease. Psychosomatics 53: 155–161.
    1. Williams ED, Steptoe A. The role of depression in the etiology of acute coronary syndrome. Curr Psychiatry Rep 2007; 9: 486–492.
    1. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580–592.
    1. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27: 2763–2774.
    1. Colbert LH, Visser M, Simonsick EM, Tracy RP, Newman AB, Kritchevsky SB et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the health, aging and body composition study. J Am Geriatr Soc 2004; 52: 1098–1104.
    1. Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE. The associations between physical activity and inflammatory markers in high-functioning older persons: macarthur studies of successful aging. J Am Geriatr Soc 2003; 51: 1125–1130.
    1. Jerstad SJ, Boutelle KN, Ness KK, Stice E. Prospective reciprocal relations between physical activity and depression in female adolescents. J Consult Clin Psychol 2010; 78: 268–272.
    1. Roshanaei-Moghaddam B, Katon WJ, Russo J. The longitudinal effects of depression on physical activity. Gen Hosp Psychiatry 2009; 31: 306–315.
    1. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR et al. Exercise for depression. Cochrane database Syst Rev 2013; 9: CD004366.
    1. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. J Psychiatr Res 2016; 77: 42–51.
    1. Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI et al. Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. J Clin Psychiatry 2011; 72: 677–684.
    1. Pedersen BK, Saltin B. Exercise as medicine—evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports 2015; 25: 1–72.
    1. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379–1406.
    1. Di Raimondo D, Tuttolomondo A, Buttà C, Casuccio A, Giarrusso L, Miceli G et al. Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exercise. Int J Clin Pract 2013; 67: 1247–1253.
    1. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol 2005; 100: 93–99.
    1. Kayambu G, Boots R, Paratz J. Early physical rehabilitation in intensive care patients with sepsis syndromes: a pilot randomised controlled trial. Intensive Care Med 2015; 41: 865–874.
    1. Palmefors H, DuttaRoy S, Rundqvist B, Börjesson M. The effect of physical activity or exercise on key biomarkers in atherosclerosis—a systematic review. Atherosclerosis 2014; 235: 150–161.
    1. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722–1727.
    1. Rethorst CD, Toups MS, Greer TL, Nakonezny Pa, Carmody TJ, Grannemann BD et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2012; 1–6.
    1. Ekkekakis P. Honey, I shrunk the pooled SMD! Guide to critical appraisal of systematic reviews and meta-analyses using the Cochrane review on exercise for depression as example. Ment Health Phys Act 2015; 8: 21–36.
    1. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013; 58: 376–385.
    1. Piette JD, Valenstein M, Himle J, Duffy S, Torres T, Vogel M et al. Clinical complexity and the effectiveness of an intervention for depressed diabetes patients. Chronic Illn 2011; 7: 267–278.
    1. Beissner K, Parker SJ, Henderson CR, Pal A, Iannone L, Reid MC. A cognitive-behavioral plus exercise intervention for older adults with chronic back pain: race/ethnicity effect? J Aging Phys Act 2012; 20: 246–265.
    1. Gaudlitz K, Plag J, Dimeo F, Ströhle A. Aerobic exercise training facilitates the effectiveness of cognitive behavioral therapy in panic disorder. Depress Anxiety 2015; 32: 221–228.
    1. Pentecost C, Farrand P, Greaves CJ, Taylor RS, Warren FC, Hillsdon M et al. Combining behavioural activation with physical activity promotion for adults with depression: findings of a parallel-group pilot randomised controlled trial (BAcPAc). Trials 2015; 16: 367.
    1. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007; 21: 374–383.
    1. Euteneuer F, Schwarz MJ, Schmidmaier R, Hennings A, Riemer S, Stapf TM et al. Blunted exercise-induced mobilization of monocytes in somatization syndromes and major depression. J Affect Disord 2014; 166: 156–164.
    1. Schlatter J, Ortuño F, Cervera-Enguix S. Monocytic parameters in patients with dysthymia versus major depression. J Affect Disord 2004; 78: 243–247.
    1. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 2004; 4: 185–192.
    1. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995; 41: 534–538.
    1. Krause DL, Riedel M, Müller N, Weidinger E, Schwarz MJ, Myint A-M. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients. Inflammopharmacology 2012; 20: 169–176.
    1. Lisi L, Camardese G, Treglia M, Tringali G, Carrozza C, Janiri L et al. Monocytes from depressed patients display an altered pattern of response to endotoxin challenge. PLoS ONE 2013; 8: e52585.
    1. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 1994; 35: 42–47.
    1. Humphreys D, Schlesinger L, Lopez M, Araya AV. Interleukin-6 production and deregulation of the hypothalamic-pituitary-adrenal axis in patients with major depressive disorders. Endocrine 2006; 30: 371–376.
    1. Cyranowski JM, Marsland AL, Bromberger JT, Whiteside TL, Chang Y, Matthews KA. Depressive symptoms and production of proinflammatory cytokines by peripheral blood mononuclear cells stimulated in vitro. Brain Behav Immun 2007; 21: 229–237.
    1. Guidi L, Bartoloni C, Frasca D, Antico L, Pili R, Cursi F et al. Impairment of lymphocyte activities in depressed aged subjects. Mech Ageing Dev 1991; 60: 13–24.
    1. Miller GE, Rohleder N, Stetler C, Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med 2005; 67: 679–687.
    1. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999; 4: 182–188.
    1. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A et al. Inflammatory markers in major depression and melancholia. J Affect Disord 2001; 63: 93–102.
    1. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175–191.
    1. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–1397.
    1. American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association: Washington, DC, USA, 1994.
    1. Wittchen H-U, Wunderlich U, Gruschitz S, Zaudig M. Strukturiertes Klinisches Interview für DSM-IV, Achse I (SKID-I). Hogrefe: Göttingen, 1997.
    1. Hautzinger M. Kognitive Verhaltenstherapie bei Depressionen. Psychologie Verlags Union: Weinheim, 2003.
    1. World Health OrganizationGlobal Recommendations on Physical Activity for Health. WHO Press: Geneva, Switzerland, 2010.
    1. Craft LL, Perna FM. The benefits of exercise for the clinically depressed. Prim Care Companion J Clin Psychiatry 2004; 6: 104–111.
    1. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR, Montoye HJ, Sallis JF et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993; 25: 71–80.
    1. Lutz R. The therapeutic concept of euthymic treatment. The little school of pleasure. MMW Fortschr Med 2005; 147: 41–43.
    1. Hautzinger M, Kühner C, Keller F. Das Beck Depressionsinventar II. Deutsche Bearbeitung und Handbuch zum BDI II. Harcourt Test Services: Frankfurt, 2006.
    1. Craig CL, Marshall AL, SjÖStrÖM M, Bauman AE, Booth ML, Ainsworth BE et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381–1395.
    1. Grigoleit J, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS ONE 2011; 6: 1–10.
    1. De Groote D, Zangerle P, Gevaert Y, Fassotte M, Beguin Y, Noizat-Pirenne F et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 1992; 4: 239–248.
    1. SAGE. Hierarchical Linear Models. Available at: . Accessed on 12 March 2016.
    1. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716–723.
    1. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6: 461–464.
    1. Tabachnick B, Fidell F. Using Multivariate Statistics. Pearson: Boston, MA, USA, 2014.
    1. Twisk J, de Boer M, de Vente W, Heymans M. Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis. J Clin Epidemiol 2013; 66: 1022–1028.
    1. Peters SAE, Bots ML, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR et al. Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models. J Clin Epidemiol 2012; 65: 686–695.
    1. Bender R, Lange S. Adjusting for multiple testing—when and how? J Clin Epidemiol 2001; 54: 343–349.
    1. Thomas E, Sokal Robert R, Jamesrohlf F. Introduction to Biostatistics, 2nd edn. W. H. Freeman and Co.: New York, NY, USA, 1987.
    1. Pearson TA. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.
    1. Ridker PM. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81–e85.
    1. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154–1162.
    1. Neefkes-Zonneveld CR, Bakkum AJ, Bishop NC, van Tulder MW, Janssen TW. Effect of long-term physical activity and acute exercise on markers of systemic inflammation in persons with chronic spinal cord injury: a systematic review. Arch Phys Med Rehabil 2015; 96: 30–42.
    1. Ribeiro F, Alves AJ, Teixeira M, Miranda F, Azevedo C, Duarte JA et al. Exercise training increases interleukin-10 after an acute myocardial infarction: a randomised clinical trial. Int J Sports Med 2012; 33: 192–198.
    1. Dimsdale JE, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980; 243: 340–342.
    1. Hong S, Dimitrov S, Pruitt C, Shaikh F, Beg N. Benefit of physical fitness against inflammation in obesity: role of beta adrenergic receptors. Brain Behav Immun 2014; 39: 113–120.
    1. Hong S, Johnson TA, Farag NH, Guy HJ, Matthews SC, Ziegler MG et al. Attenuation of T-lymphocyte demargination and adhesion molecule expression in response to moderate exercise in physically fit individuals. J Appl Physiol 2004; 98: 1057–1063.
    1. Euteneuer F, Ziegler MG, Mills PJ, Rief W, Dimsdale JE. In Vivo β-adrenergic receptor responsiveness: ethnic differences in the relationship with symptoms of depression and fatigue. Int J Behav Med 2013; 21: 843–850.
    1. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996; 108: 374–381.
    1. Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N et al. Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial. Biol Psychiatry 2015; 78: 721–729.
    1. Riemann D. Insomnia and comorbid psychiatric disorders. Sleep Med 2007; 8: S15–S20.
    1. Sivertsen B, Salo P, Mykletun A, Hysing M, Pallesen S, Krokstad S et al. The bidirectional association between depression and insomnia: the HUNT study. Psychosom Med 2012; 74: 758–765.
    1. Kéri S, Szabó C, Kelemen O. Expression of Toll-like receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder. Brain Behav Immun 2014; 40: 235–243.
    1. Taylor CB, Conrad A, Wilhelm FH, Strachowski D, Khaylis A, Neri E et al. Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk? J Psychiatr Res 2009; 43: 1246–1252.
    1. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74: 658–670.
    1. Zhang D-F, Song X-T, Chen Y-D, Yuan F, Xu F, Zhang M et al. Prognostic performance of interleukin-10 in patients with chest pain and mild to moderate coronary artery lesions-an 8-year follow-up study. J Geriatr Cardiol 2016; 13: 244–251.
    1. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109–2114.
    1. Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med 2011; 124: 724–730.
    1. Han X, Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost 2014; 113: 505–512.
    1. Parissis JT, Farmakis D, Nikolaou M, Birmpa D, Bistola V, Paraskevaidis I et al. Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart Fail 2009; 11: 967–972.
    1. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15: 199–226.
    1. Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med 1993; 55: 364–379.
    1. Sjögren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun 2006; 20: 270–278.
    1. Brühmann BA, Schmidt ME, Steindorf K. Assessment of physical activity in epidemiological studies: are questionnaires obsolete in the era of accelerometry? GMS Med Inform Biom Epidemiol 2014; 10; doi: 10.3205/mibe000155.
    1. Wanner M, Probst-Hensch N, Kriemler S, Meier F, Autenrieth C, Martin BW. Validation of the long international physical activity questionnaire: Influence of age and language region. Prev Med Rep 2016; 3: 250–256.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner